GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Purchase Of Business

Akari Therapeutics (FRA:CLA) Purchase Of Business : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Purchase Of Business?

Akari Therapeutics's purchase of business for the three months ended in Jun. 2024 was €0.00 Mil. It means Akari Therapeutics spent €0.00 Mil on purchasing business. Akari Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Mar. 2024 ), Akari Therapeutics spent the same money on purchasing business in Jun. 2024 (€0.00 Mil).

Akari Therapeutics Purchase Of Business Historical Data

The historical data trend for Akari Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Purchase Of Business Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Purchase Of Business
Comparable Companies
IGC MYMD ENTX INDP PMCB AZTR EQ IGXT ONCT TCRT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AKTX:USA
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Website
https://www.akaritx.com
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.